JAK inhibitors: A home run for GVHD patients?

Blood

Volumn 123, Issue 24, 2014, Pages 3691-3693

  Teshima, Takanori ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 23; INTERLEUKIN 6; RUXOLITINIB;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; CLINICAL TRIAL (TOPIC); CYTOKINE PRODUCTION; DRUG DOSE COMPARISON; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; LYMPHOCYTE DIFFERENTIATION; MYELOFIBROSIS; NONHUMAN; NOTE; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; PROPHYLAXIS; REGULATORY T LYMPHOCYTE; THROMBOCYTOPENIA;

ANIMALS; FEMALE; GRAFT VS HOST DISEASE; HUMANS; JANUS KINASE 2; MALE; PROTEIN KINASE INHIBITORS; PYRAZOLES;

EID: 84902602755     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-04-570325     Document Type: Note

References (6)

1. Spoerl S, Mathew NR, Bscheider M, et al. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. Blood. 2014;123(24):3832-3842.
2. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9): 787-798.
3. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799-807.
4. Heine A, Held SA, Daecke SN, et al. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood. 2013;122(7):1192-1202.
5. Heine A, Brossart P, Wolf D. Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? Blood. 2013;122(23): 3843-3844.
6. Satake A, Schmidt AM, Nomura S, Kambayashi T. Inhibition of calcineurin abrogates while inhibition of mTOR promotes regulatory T cell expansion and graft-versus-host disease protection by IL-2 in allogeneic bone marrow transplantation. PLoS ONE. 2014;9(3):e92888.